Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study

Kimberly K. Leslie, Virginia L. Filiaci, Adrianne R. Mallen, Kristina W. Thiel, Eric J. Devor, Katherine Moxley, Debra Richardson, David Mutch, Angeles Alvarez Secord, Krishnansu S. Tewari, Megan E. McDonald, Cara Mathews, Casey Cosgrove, Summer Dewdney, Yovanni Casablanca, Amanda Jackson, Peter G. Rose, Xun Clare Zhou, Michael McHale, Heather LankesDouglas A. Levine, Carol Aghajanian

Research output: Contribution to journal › Article › peer-review

43 Scopus citations

Sort by
Weight
Alphabetically

Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study

Fingerprint

Medicine & Life Sciences